Brainsway Ltd · TASE:BWAY
Brainsway — Investor Presentation (November 2017)
22 slides from Brainsway's investor presentation, November 2017
Slide 1: Company Presentation
Company Presentation Yaacov Michlin, CEO November 2017
Slide 2: Forward-looking information (Hebrew)
מידע צופה פני עתיד מצגת זו של בריינסווי בע"מ ("בריינסווי") לא נועדה לתת תיאור כולל ומלא של פעילות החברה או של הנושא המרכזי של המצגת באופן מפורט ואינה יכולה להוות בסיס עבור קבלת החלטה על שיתוף פעולה כלשהו עם בריינסווי. מצגת זו נערכה בעיקרה לשם הנוחות .על מנת לקבל תמונה מלאה על בריינסווי ופ
Slide 3: Company Highlights
Company Highlights Deep TMS system FDA cleared CE marked for MDD, Reimbursement in US: for MDD OCD and 11 additional ~95% covered indications commercial and Medicare ~20K Robust Strong IP Business model - MDD patients treated to clinical pipeline portfolio $23M lease portfolio day in committed reven
Slide 4: Recent Activities Highlights
Recent Activities Highlights • Successful and consistent implementation of Lease Focused Business Model with strong Q3 Results and continuous growth in Backlog • OCD submission to FDA (as reported on 3.10.17) • Smoking Cessation study progress • New Stimulator development • Top management recruitmen
Slide 5: Brainsway Deep TMS Technology
Brainsway Deep TMS Technology 1 Rapidly changing electric field in the brain, leading to axonal depolarization and action potentials. 2 Brainsway proprietary coils optimize the utilization of the energy and allow for DEEP, noninvasive stimulation of the brain. 3 2.5 times deeper than Standard TMS. D
Slide 6: Brainsway's Procedure
Brainsway’s Procedure • Non-invasive • No anesthesia • Well-tolerated • Each treatment session lasts approximately 20 minutes • Typical treatment protocol: 4 weeks of 5 sessions per week. Continuation of 2 weekly sessions, for 8 additional weeks. • Platform technology for a variety of indications 6
Slide 7: TMS Competitive Landscape
TMS Competitive Landscape The Brainsway Advantage The only non invasive, non systemic deep brain stimulation Electroconvulsive Therapy Over 20,000 patient have been already treated Antidepressants The strongest clinical pipeline Proven commercial success in the US The shortest, clinically proven tre
Slide 8: OCD Results – H7 Coil
OCD Results – H7 Coil – (Released 11.6.2017) 8
Slide 9: OCD Response Rates
OCD Response Rates Sham Real 54.76% 38.10% 26.67% p=0.0033 11.10% p=0.0076 N= 94 9 RESPONSE RATE PARTIAL RESPONSE RATE
Slide 10: Mean change in YBOCS from Baseline
Mean change in YBOCS from Baseline Real Sham/ Placebo Data on SSRI medications : based on FDA labeling, and 7 effects 6.7 observed in separate DBPC 5.7 studies for 5 ∆=3 each SSRI 4.5 ∆=3.1 medication ∆=2.85 4 ∆=2.5 3.6 2.85 ∆=4 2 1 Brainsway 6 weeks 10
Slide 11: Mean change in YBOCS from Baseline
Mean change in YBOCS from Baseline Data on SSRI medications Real Sham/Placebo based on meta- analysis (Soomro et al., 2008) 7 5.57 5.55 6.7 4.47 ∆=3.36 ∆=2.45 3.64 3.12 ∆=3.87 3.6 ∆=3.07 1.68 1.4 Brainsway 6 weeks 11
Slide 12: H7 coil investigator quotes
“The H7 coil we developed for the stimulation of the anterior cingulate cortex region in the brain has now demonstrated significant potential in a large multicenter study conducted by key opinion leaders at world-leading institutions.” Prof. Abraham Zangen, one of the inventors of the Deep TMS techn
Slide 13: Strong Foundation, Promising Future
Strong Foundation, Promising Future Brainsway is the only provider with the ability to treat a wide range of brain disorders with non-pharmacological, non-invasive, safe approach 13
Slide 14: Smoking Multicenter Study – H4 Coil
Smoking Multicenter Study – H4 Coil [Results expected H2/2018] • 190 subjects were randomized out of 234 • 135 subjects completed the study out of 164 • 10 sites in US and 2 in Israel Phase 1 Phase 2 Phase 3 Screening Weeks 1-3: Daily treatment Weeks 4-6 : Once a week Follow up 4M visit Total : 18 t
Slide 15: Smoking Cessation Feasibility Study
Smoking Cessation- Brainsway Feasibility Study Subjects Abstinent (%) after 6 months 35% 30% 33% 25% Subjects Abstinent (%) 20% after 6 month 15% • Impaired circuitry involving the insula and PFC is implicated in 10% the addiction for both opiates, nicotine and cocaine* 5% 9% • For example craving f
Slide 16: Strong R&D Pipeline
Strong R&D Pipeline Multi-channel stimulator • Breakthrough in TMS treatment • Patent-protected • Allows treatment of the most complicated brain disorders • Combined synchronized differential activation of different brain regions to enhance treatment efficacy • enables focal activation of deep brain
Slide 17: Scientific Advisory Board
Scientific Advisory Board 17
Slide 18: New Recruitments – Sales & Marketing
New Recruitments – Sales & Marketing Dr. Sundeep Lal Irit Aish Career Highlights: Career Highlights: • Served in a variety of senior S&M roles at • Served as Vice President, Strategy, TEVA from 2005-2014; Business Development and Healthcare • Led marketing activities of Copaxone in major Solutions f
Slide 19: New Board Member
New Board Member (subject to GM approval) Karen Sarid - BOD Member Career Highlights: • Seasoned senior executive with leadership roles at many Israeli and international medical device companies, including Alma Lasers, Ltd., Syneron Medical Ltd., Orex Computed Radiography and ESC Medical Systems • C
Slide 20: Brainsway 1st place in Global Innovation
First in Global Innovation • IIA and Chinese Science office Road Show • 160 Israeli Life Science companies • 40 short listed • 10 finalists presentations Brainsway 1st place 20
Slide 21: Disclaimer
Disclaimer • THIS PRESENTATION OF BRAINSWAY LTD. (“BRAINSWAY”) DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN INFORMATION PERTAINING TO THE SUBJECT MATTER HEREOF AND MAY NOT BE RELIED UPON FOR MAKING ANY COLLABORATION DECISION WITH RESPECT TO BRAINSWAY. • THE INFORMATION PROVIDED HERERIN IS PROV
Slide 22: Thank You!
Thank You!